MRD as primary endpoint

Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies?  With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami

MAT-BE-2200984 (1.0) 12 2022
Medipodcast

Medipodcast

Lees zijn biografie

Misschien bent u ook geĂŻnteresseerd in deze inhoud:

Welkom!

Log hieronder in

Create New Account!

Fill the forms below to register

*By registering into our website, you agree to the Terms & Conditions and Privacy Policy.

Retrieve your password

Please enter your username or email address to reset your password.

Add New Playlist

Maak uw account aan!

Vul onderstaand formulier in om uw account aan te maken

Heeft u al een account? Login
-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00